Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study

Autor: Larry J. Copeland, Mark F. Brady, Robert A. Burger, William H. Rodgers, Helen Q. Huang, David Cella, David M. O'Malley, Daron G. Street, Krishnansu S. Tewari, David P. Bender, Robert T. Morris, William J. Lowery, David S. Miller, Summer B. Dewdney, Nick M. Spirtos, Shashikant B. Lele, Saketh Guntupalli, Frederick R. Ueland, Gretchen E. Glaser, Robert S. Mannel, Philip J. DiSaia

Publikováno v: Journal of Clinical Oncology. 40:4119-4128

PURPOSE To compare taxane maintenance chemotherapy, paclitaxel (P) and paclitaxel poliglumex (PP), with surveillance (S) in women with ovarian, peritoneal, or fallopian tube (O/PC/FT) cancer who attained clinical complete response after first-line pl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::703d9b1ede924d762a06acf7ea13d7aa
https://doi.org/10.1200/jco.22.00146

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Autor: Matthew A. Powell, Virginia L. Filiaci, Martee L. Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu S. Tewari, Larry J. Copeland, Angeles A. Secord, David G. Mutch, Alessandro Santin, David P. Warshal, Nick M. Spirtos, Paul A. DiSilvestro, Olga B. Ioffe, David S. Miller

Publikováno v: J Clin Oncol

PURPOSE This phase III randomized trial ( NCT00954174 ) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS). PATIENTS AND METHODS Adults with chemothe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb2cf390d0faab618628a4901df277c2
https://pubmed.ncbi.nlm.nih.gov/35044808

Impact of Homologous Recombination Status and Responses With Veliparib Combined With First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study

Autor: Elizabeth M. Swisher, Carol Aghajanian, David M. O'Malley, Gini F. Fleming, Scott H. Kaufmann, Douglas A. Levine, Michael J. Birrer, Kathleen N. Moore, Nick M. Spirtos, Mark S. Shahin, Thomas J. Reid, Michael Friedlander, Karina Dahl Steffensen, Aikou Okamoto, Vasudha Sehgal, Peter J. Ansell, Minh H. Dinh, Michael A. Bookman, Robert L. Coleman

Publikováno v: Swisher, E M, Aghajanian, C, O'Malley, D M, Fleming, G F, Kaufmann, S H, Levine, D A, Birrer, M J, Moore, K N, Spirtos, N M, Shahin, M S, Reid, T J, Friedlander, M, Steffensen, K D, Okamoto, A, Sehgal, V, Ansell, P J, Dinh, M H, Bookman, M A & Coleman, R L 2022, ' Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study ', Gynecologic Oncology, vol. 164, no. 2, pp. 245-253 . https://doi.org/10.1016/j.ygyno.2021.12.003

OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with first-line chemotherapy and continued as maintenance for patients with ovarian carcinoma enrolled regardless of chemotherapy response or biomarker

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4581455fdf487d12d2578e534388cdd5
https://doi.org/10.1097/01.ogx.0000827620.82650.68

A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study

Autor: Paul Sabbatini, Kian Behbakht, Lee-may Chen, Carolyn Y. Muller, Roisin E. O'Cearbhaill, Carol Aghajanian, Benedict B. Benigno, Krishnansu S. Tewari, Emily Berry, Parviz Hanjani, Heather A. Lankes, Joseph A. Lucci, Nick M. Spirtos, Matthew A. Powell, Wei Deng

Publikováno v: Gynecologic Oncology. 155:393-399

Objective Early-phase data have demonstrated induction of antibody responses to a polyvalent vaccine conjugate (Globo-H, GM2, MUC1-TN, TF) with adjuvant OPT-821. We sought to determine if this combination decreases the hazard of progression or death

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f89f8569205a196686ac45642bc56a77
https://doi.org/10.1016/j.ygyno.2019.09.015

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

Autor: Nick M. Spirtos, James J. Burke, David Miller, Jae Weon Kim, Marcus E. Randall, Paul DiSilvestro, Robert S. Mannel, Virginia L. Filiaci, Penny R. Anderson, William Small, Ritu Salani, Keith Terada, Helen J. Huang, Wendy R. Brewster, Vivian E. von Gruenigen, Carol Aghajanian, Catheryn M. Yashar, D. Scott McMeekin, Thomas J. Rutherford

Publikováno v: Journal of Clinical Oncology. 37:1810-1818

PURPOSE The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa2c4f6488b1ad549a0d186d41c35360
https://doi.org/10.1200/jco.18.01575